<DOC>
	<DOCNO>NCT00898287</DOCNO>
	<brief_summary>The purpose study identify dose P276-00 safely administer along Gemcitabine examine safety efficacy combination treatment advance pancreatic cancer .</brief_summary>
	<brief_title>Safety Efficacy Study P276-00 Combination With Gemcitabine Patients With Advanced Pancreatic Cancer</brief_title>
	<detailed_description>This study open label multicenter trial evaluate safety efficacy P276-00 combination Gemcitabine subject locally advanced metastatic pancreatic cancer . Primary objective part A determine maximum tolerate dose ( MTD ) P276-00 combination Gemcitabine part B evaluate efficacy combination subject locally advanced metastatic pancreatic cancer . In part A , cohort 3 subject enrol start dose level P276-00 100 mg/m2/ day give intravenously ( IV ) day 1 day 5 every 21 day . This constitute one cycle P276-00 . If dose well tolerated next cohort enrol high dose level P276-00 . P276-00 dose escalation continue MTD P276-00 combination Gemcitabine determine . The subsequent dose level P276-00 140 mg/m2/day 185 mg/m2/day . In part B ten subject evaluate MTD P276-00 combination Gemcitabine evaluate efficacy combination . Dose Gemcitabine part study 1000mg/m2 30mins every week 7 week follow gap one week 3 weekly dos every 4 week . Subjects treat six cycle P276-00 combination Gemcitabine evidence disease progression unacceptable toxicity . Safety evaluation perform regular interval mean record vital parameter , physical examination laboratory investigation hematology biochemistry . Efficacy assessment perform mean weekly record pain intensity , analgesic consumption , change weight performance status evaluation clinical benefit response mean CT scan end every 2 cycle evaluation tumor response RECIST ( Response Evaluation Criteria Solid Tumors )</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>1 . Histologically cytologically confirm diagnosis infiltrating ductal adenocarcinoma pancreas . 2 . Chemonaive patient i.e . patient must receive chemotherapy biologic/targeted anticancer therapy adenocarcinoma pancreas . 3 . Locally advanced inoperable pancreatic cancer . 4 . Patients either sex , age &gt; = 18 year . 5 . Karnofsky performance status &gt; = 60 % . 6 . Adequate bone marrow reserve : white blood cell ( WBC ) count &gt; = 4 x 109/l , Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/l , platelet &gt; = 100 x 109/l , hemoglobin &gt; = 10 g/dl . 7 . Adequate liver function : bilirubin &lt; = 1.5 time upper normal value , ALT/AST/ alkaline phosphatase less 3 time upper normal value ( unless due liver metastasis case bilirubin less 3 time upper normal value , ALT/AST le 4 time upper normal value , alkaline phosphatase without limit ) . 8 . Adequate renal function : creatinine ≤ 1.5 time upper normal value . 9 . If female : Childbearing potential either terminate surgery , radiation , menopause , attenuate use least 2 approve contraceptive method ( least one barrier method ) 4 week stop study treatment . Negative urine βHCG test within 1 week prior protocol entry childbearing potential terminate . 10 . Additional inclusion criterion part B : Patient satisfy least one follow criterion cycle 1 day 1 : Karnofsky performance status 60 70 Baseline pain intensity score &gt; = 20 mm 1 . Inability / unwillingness give consent . 2 . Pregnant breast feed woman . 3 . Brain metastasis ( active inactive ) . 4 . Serious concomitant systemic disorder incompatible study ( discretion investigator ) . 5 . Patients know suffer infection HIV , Hepatitis C Hepatitis B . 6 . Patients receive investigational drug within 1 month prior Day 1 protocol treatment . 7 . Patients QTc &gt; 450 msec 12lead standard electrocardiogram ( ECG ) . 8 . Major surgery within 2 week prior protocol treatment . 9 . Radiotherapy &gt; 10 % bone marrow . 10 . Patients 3rd space fluid accumulation ( ascites , pleural effusion ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Locally advanced metastatic adenocarcinoma pancreas</keyword>
</DOC>